Junshi Biosciences’ TAB009/JS009 Receives the US FDA’s Approval for the Treatment of Advanced Solid Tumors
Shots:
- The US FDA has approved an IND application for TAB009/JS009 (anti-CD112R mAb) to treat advanced solid tumors
- In the pre-clinical in vivo PD studies, TAB009/JS009 + TAB006/JS006 showed significant synergistic anti-tumor effects. Additionally, the combination along with toripalimab can increase T-cell activation and improve the efficacy of clinical treatment
- The company plans to actively explore drug combinations to maximize the synergistic anti-tumor potential of its self-developed products. The therapy is designed to bind specifically to CD112R with high affinity and effectively blocks the interaction b/w CD112R and CD112 to activate & proliferate T & NK cells
Ref: Globe Newswire | Image: Globe Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
